Abstract
The effectiveness and tolerance of a non-amphetaminic anorexiant drug has been evaluated in a short-term and in a long-term clinical trial in simple obesity and in refractory obesity.
In the short-term ‘crossover’ trial, a more evident effectiveness and tolerance result when the anorexiant is given in a late phase of treatment.
The association of an anorexiant drug with the hypocaloric diet was seen to be effective in the treatment of so-called refractory obesity.
In the evaluation of the long-term treatment it is seen that weight loss is greater and remains so for longer periods in patients receiving anorexiant, as compared to controls. This is related to a better maintenance of a restricted calorie regimen.
Mazindol did not affect the improvement of glucose tolerance and insulin secretion which follows the weight reduction.
Get full access to this article
View all access options for this article.